ProQR Therapeutics

$4.48
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.36 (-7.44%) Today
$0.00 (0.00%) As of 9:46 PM UTC after-hours

Why Robinhood?

You can buy or sell PRQR and other stocks, options, and ETFs commission-free!

About PRQR

ProQR Therapeutics NV operates as a biopharmaceutical company, which engages in the discovery and development of Ribonucleic Acid RNA based therapeutics for the treatment of genetic disorders. Its initial focus is on the development of a disease-modifying therapy for the treatment of cystic fibrosis. The company was founded by Daniel de Boer, Gerard Platenburg, Henri Termeer and Dinko Valerio on February 21, 2012 and is headquartered in Leiden, the Netherlands. The listed name for PRQR is ProQR Therapeutics N.V. Ordinary Shares.

CEO
Daniel Anton de Boer
Employees
154
Headquarters
Leiden, Zuid-Holland
Founded
2012
Market Cap
210.37M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
566.34K
High Today
$4.85
Low Today
$4.30
Open Price
$4.80
Volume
455.72K
52 Week High
$8.69
52 Week Low
$3.40

PRQR Earnings

-$0.43
-$0.29
-$0.14
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Available Feb 25, Pre-Market

You May Also Like

BOB
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure